United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
| Revenue (TTM) | $3.15B |
| Gross Profit (TTM) | $2.72B |
| EBITDA | $1.50B |
| Operating Margin | 42.20% |
| Return on Equity | 19.30% |
| Return on Assets | 11.60% |
| Revenue/Share (TTM) | $72.85 |
| Book Value | $149.97 |
| Price-to-Book | 3.35 |
| Price-to-Sales (TTM) | 6.91 |
| EV/Revenue | 5.8 |
| EV/EBITDA | 10.92 |
| Quarterly Earnings Growth (YoY) | 13.40% |
| Quarterly Revenue Growth (YoY) | -1.90% |
| Shares Outstanding | $42.89M |
| Float | $39.21M |
| % Insiders | 2.03% |
| % Institutions | 100.06% |
Volatility is currently expanding
United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.
UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.
United Therapeutics NASDAQ: UTHR reported second-quarter 2026 revenue of approximately $783 million, essentially flat from the first quarter, as competitive pressure affected sales of its nebulized TYVASO therapy. Company executives said they expect stronger performance in the second half of the year but did not reaffirm or update previous 2026 revenue-growth expectations.
United Therapeutics Corporation (UTHR) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
United Therapeutics (UTHR) came out with quarterly earnings of $7.27 per share, beating the Zacks Consensus Estimate of $6.82 per share. This compares to earnings of $6.41 per share a year ago.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2026. Total revenues in the second quarter of 2026 decreased by two percent year-over-year to $783.3 million, compared to $798.6 million in the second quarter of 2025. “We just submitted what we believe are two of the most important NDAs in rare pulmonary disease history: ralinepag t.
Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that The Lancet has published full results of its ADVANCE OUTCOMES study, available here. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. Ralinepag reduced the risk of a clinical worsening event by 55% compared with placebo in patients with PAH (hazard ratio 0.45, 95% CI [0.33-0.
Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on UTHR and any ticker you trade — then tracks every position and per-strategy win rate.
